PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. (Q54478528)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. (English)

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

author name string

Edna F Choo

1

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Chee M Ng

2

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Leanne Berry

3

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Marcia Belvin

4

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Nicholas Lewin-Koh

5

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Laurent Salphati

7

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

publication date

7 October 2012

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

71

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

1

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

133-143

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

https://scigraph.springernature.com/pub.10.1007/s00280-012-1988-6

0 references

The akt kinase: molecular determinants of oncogenicity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Modeling of tumor growth and anticancer effects of combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Is B-Raf a good therapeutic target for melanoma and other malignancies?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Scaling pharmacodynamics from in vitro and preclinical animal studies to humans

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Contributions of human tumor xenografts to anticancer drug development

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Raf kinases: oncogenesis and drug discovery

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Tumor models for efficacy determination

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphory

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Back to the roots: the remarkable RAF oncogene story

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1988-6

21 January 2018

Identifiers

10.1007/S00280-012-1988-6

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23053270

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54478528&oldid=1235312166"